This request would require that all
inhalation solutions for nebulization products be sterile. The
proposed sterility requirements for inhalation solutions serves a
compelling Federal interest in that it prevents dangerous
microbiological contamination that can lead to serious adverse
health consequences. Many patients using inhalation solution
products for nebulization have chronic obstructive airway disease
or cystic fibrosis or are immunocompromised.